Medline (NASDAQ:MDLN) Coverage Initiated at Wells Fargo & Company

Equities researchers at Wells Fargo & Company started coverage on shares of Medline (NASDAQ:MDLN) in a report issued on Monday, Marketbeat.com reports. The brokerage set an “equal weight” rating and a $42.00 price target on the stock. Wells Fargo & Company‘s target price points to a potential upside of 3.65% from the stock’s previous close.

Several other analysts also recently weighed in on the company. Stifel Nicolaus began coverage on Medline in a report on Monday. They issued a “buy” rating and a $46.00 price objective for the company. Wolfe Research started coverage on shares of Medline in a research report on Monday. They set an “outperform” rating and a $47.00 target price on the stock. Wall Street Zen raised shares of Medline to a “hold” rating in a research report on Saturday. Robert W. Baird assumed coverage on shares of Medline in a research note on Monday. They set an “outperform” rating and a $48.00 price objective on the stock. Finally, Sanford C. Bernstein started coverage on shares of Medline in a report on Monday. They set an “outperform” rating and a $49.00 price objective on the stock. Twenty-one analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Medline presently has a consensus rating of “Moderate Buy” and an average target price of $47.26.

Medline Stock Down 1.8%

Shares of NASDAQ MDLN opened at $40.52 on Monday. Medline has a twelve month low of $34.89 and a twelve month high of $45.50.

Insider Activity

In other news, Director Charles N. Mills bought 2,579,310 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The stock was bought at an average price of $29.00 per share, with a total value of $74,799,990.00. Following the completion of the transaction, the director directly owned 2,441,379 shares of the company’s stock, valued at approximately $70,799,991. The trade was a -1,870.00% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of Medline stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $28.37, for a total transaction of $172,727,085.27. Following the completion of the transaction, the insider directly owned 4,806,160 shares in the company, valued at $136,350,759.20. This represents a 55.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information.

Key Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Jefferies started coverage with a “Buy,” highlighting Medline’s ~$25 billion supply-chain scale as a durable competitive advantage that supports growth and margin expansion. Medline’s $25 bln supply chain scale wins Jefferies “buy” in coverage debut
• Positive Sentiment: TipRanks coverage of new sell‑side initiations (e.g., J.P. Morgan) emphasizes Medline’s prime‑vendor position, branded mix shift and margin expansion runway — factors analysts say justify a premium valuation. Medline, Inc. Class A: Prime Vendor Wins, Branded Mix Shift, and Margin Expansion Support Buy Rating and Premium Valuation
• Positive Sentiment: Multiple outlets report a broad set of bullish analyst initiations after the IPO (Buy/Overweight ratings and constructive price targets), which is amplifying positive sentiment and buying interest. Analysts initiate Medline with bullish ratings after blockbuster IPO
• Positive Sentiment: Media and TV coverage — including praise from commentators such as Jim Cramer — is raising retail and institutional visibility for MDLN, supporting near‑term momentum. Jim Cramer Medline: “It’s a Terrific Company”
• Neutral Sentiment: A valuation note points out shares are trading near a DCF estimate after the recent moves, suggesting limited near‑term upside unless execution or margin beats occur — a reminder that much of the positive view is already priced in. Medline (MDLN) Valuation Check As Shares Trade Near DCF Estimate After Recent Moves

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.